Moderna

Q3 2026
Speakers

Nov 6, 2026 · 58 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good day and thank you for standing by. Welcome to Moderna's third quarter twenty twenty six conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message device and your hand is raised.

To withdraw your question, please press star one one again. Please be advised today's conference is being recorded.
?I would now like to hand the conference over to your speaker today, Lavina Tulupdar. Please go

Passages & reports (4)
  • Good day and thank you for standing by. Welcome to Moderna's third quarter twenty twenty s…
  • your telephone. You will then hear an automated message device and your hand is raised. To…
  • I would
  • now like to hand the conference over to your speaker today, Lavina Tulupdar. Please go

Speaker unclear

?ahead.

Passages & reports (1)
  • ahead.

Speaker 1

Unverified voice label

Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's third quarter 2026 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investors section of our website. On today's call are Stefan Bonzel, our Chief Executive Officer, Stephen Hogue, our President, Jamie Mock, our Chief Financial Officer, and David Berman, our Chief Development Officer.

Before we begin, please note that this call will include forward looking statements made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward looking statements.

With that, I will turn the call over to Stefan.

Passages & reports (4)
  • Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to …
  • On today's call are Stefan Bonzel, our Chief Executive Officer, Stephen Hogue, our Preside…
  • Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Please see slid…
  • expressed or implied in these forward looking statements. With that, I will turn the call …

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you, Lavina. Good morning or good

Passages & reports (1)
  • you, Lavina. Good morning or good

Speaker 2

Unverified voice label

afternoon, everyone. Thank you for joining us. I will start today with a review of third quarter. Jamie will then cover our financial results and outlook, followed by Steven with our current business updates in infectious disease. David will then review our clinical progress in oncology and rare diseases. ?And I will come back quickly for a close on our key value drivers before QA.

Passages & reports (3)
  • afternoon, everyone. Thank you for joining us. I will start today with a review of third q…
  • And
  • I will come back quickly for a close on our key value drivers before QA.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

Moderna team delivered a great third quarter, generating $1.3 billion in revenues, representing 29% growth year over year. Importantly, this strong commercial performance translated into $200 million in net income for the quarter. We also ended the quarter with a strong balance sheet with $8 billion in cash and investments, reflecting a combination of solid operational and commercial execution, along with a highly successful convertible debt financing. ?

And
we continue to demonstrate financial discipline across a company, reducing cash cost by 10% compared to the third quarter of last ?year. Together, these strong results underscore our ability to deliver strong commercial performance while maintaining financial discipline ?and strengthening our financial position. During the quarter, we achieved several important milestones across our pipeline and our business. USFD approval and fusiva, making more than a fifth approved product and the first MRN-based influenza vaccine to reach the market.

In Canada, we secured approvals of both MFUCIVA
and MCOFLU yesterday, ?the local brand M for MCombriax, further expanding our respiratory portfolio internationally. In oncology, we are very proud to present positive phase three data for intismaran autogene, our individualized cancer therapy being developed in partnership with Merck.

Passages & reports (11)
  • Moderna team delivered a great third quarter, generating $1.3 billion in revenues, represe…
  • billion in cash and investments, reflecting a combination of solid operational and commerc…
  • And
  • we continue to demonstrate financial discipline across a company, reducing cash cost by 10…
  • year.
  • Together, these strong results underscore our ability to deliver strong commercial perform…
  • and
  • strengthening our financial position. During the quarter, we achieved several important mi…
  • and MCOFLU yesterday,
  • the
  • local brand M for MCombriax, further expanding our respiratory portfolio internationally. …

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

result demonstrated a significant clinical benefit with a 42% reduction in the risk of recurrence or death in patients with verse melanoma. An additional analysis suggesting an even greater benefit of 49% reduction in the risk of recurrence or death in patients who received at least one dose of intismeran as planned. Importantly, this marked the first combination immunotherapy regimen to demonstrate additional benefits of a ketrain alone ?in the adjuvant melanoma setting, representing a significant milestone for melanoma patients and the families around the world.

David will discuss these results in greater details. We also took an important step to further strengthen our financial position. During the quarter,
?we raised $3 billion through a 0% convertible no debt, securing long-term capital on highly attractive terms. After accounting for the purchase of CAPCOs designed to mitigate potential future dilution and fees, ?we raised approximately $2.6 billion in ed possible.

Passages & reports (8)
  • result demonstrated a significant clinical benefit with a 42% reduction in the risk of rec…
  • planned. Importantly, this marked the first combination immunotherapy regimen to demonstra…
  • in
  • the adjuvant melanoma setting, representing a significant milestone for melanoma patients …
  • we
  • raised $3 billion through a 0% convertible no debt, securing long-term capital on highly a…
  • we
  • raised approximately $2.6 billion in ed possible.

Speaker unclear

?This

Passages & reports (1)
  • This

Speaker 2

financing strengths ?are ability to invest in the growth of oncology business, ?a key strategic priority for Moderna as we approach candidate important clinical milestones. In Global Health, our Ebola vaccine candidate, MRNA 1469, developed in collaboration with CEPI, was selected to advance into phase 2.3 following a recommendation from the WHO Technical Advisory Group. ?I am extremely proud of a performance delivered by the team in Q4.

Strong sales growth,

Passages & reports (7)
  • financing strengths
  • are
  • ability to invest in the growth of oncology business,
  • a
  • key strategic priority for Moderna as we approach candidate important clinical milestones.…
  • I
  • am extremely proud of a performance delivered by the team in Q4. Strong sales growth,

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 2

Teasmeran Positive Phase 3 and the converted financing. I'm also very pleased and happy to welcome back Juan Andres to Moderna Executive Committee. Many of you will remember Juan for his previous time at Moderna, where he played a critical role in building and scaling our global manufacturing network during the pandemic. ?He also led the scale out of individualized manufacturing for Intismeran author gene.

He knows our company, our technology, and our culture extremely
?well. As we enter this next phase of Modana's growth with an expanded commercial portfolio and important opportunities ahead in oncology, having Wangback on the team will be invaluable. ?I am personally very excited ?to be working with him again. ?And I know the entire Modana team is delighted to welcome him back. With that, ?I turn to Jamie.

Passages & reports (14)
  • Teasmeran Positive Phase 3 and the converted financing. I'm also very pleased and happy to…
  • pandemic.
  • He
  • also led the scale out of individualized manufacturing for Intismeran author gene. He know…
  • well.
  • As we enter this next phase of Modana's growth with an expanded commercial portfolio and i…
  • I
  • am personally very excited
  • to
  • be working with him again.
  • And
  • I know the entire Modana team is delighted to welcome him back. With that,
  • I
  • turn to Jamie.

Speaker 3

Unverified voice label

Today I'll begin with a ?review of our third quarter financial performance, followed by an update on our 2026 financial framework. Let me start with our commercial performance on slide eight. We delivered a strong third quarter with revenue of $1.3 billion, bringing our year-to-date revenue to $1.8 billion. ?Our geographic mix for the quarter was approximately 60% US and 40% international. Both the US and international markets delivered stronger than expected revenue in 3Q, driven by a mix of increased demand, operational execution, and timing of shipments between the third and fourth quarters. ?

As
mentioned in prior calls, we forecasted two primary growth drivers in 2026 increased M Nex Spike adoption and growth in our strategic partnerships in the UK, Canada, and Australia. ?In the US, while the vaccination season is still ongoing, we have seen increased uptake of M Nex Spike, and vaccination rates have been relatively stable versus the prior ?year. Internationally, our teams have executed well, particularly in the UK and Canada.

Year-to-date international revenue of $900 million is already $200 million ahead of the full year we delivered in 2025. Based on a strong start to the season, combined with the visibility we have into the fourth quarter, we are increasing our
full year revenue framework ?to a range of 15 to 25 percent growth, which exceeds our prior framework of up to 10% growth. We continue to expect an approximately even split between U.S.

and international revenue for the full

Passages & reports (14)
  • Today I'll begin with a
  • review of our
  • third quarter financial performance, followed by an update on our 2026 financial framework…
  • Our
  • geographic mix for the quarter was approximately 60% US and 40% international. Both the US…
  • As
  • mentioned in prior calls, we forecasted two primary growth drivers in 2026 increased M Nex…
  • In
  • the US, while the vaccination season is still ongoing, we have seen increased uptake of M …
  • year.
  • Internationally, our teams have executed well, particularly in the UK and Canada. Year-to-…
  • full year revenue framework
  • to
  • a range of 15 to 25 percent growth, which exceeds our prior framework of up to 10% growth.…

Speaker unclear

?year. Now

Passages & reports (1)
  • year. Now

Speaker 3

let me turn to our third quarter financial performance on slide nine. As I just mentioned, total revenue was $1.3 billion for the quarter, up 29% from last year, primarily driven by higher COVID sales. Cost of sales for the quarter was $318 million, representing 24% of total revenue for the quarter. This was a 54% increase in our cost of sales from Q3 last year, primarily driven by higher product sales volume and other manufacturing related costs.

We remain on track to drive significant gross margin improvements in 2026, excluding the $900 million litigation charge.

Passages & reports (2)
  • let me turn to our third quarter financial performance on slide nine. As I just mentioned,…
  • This was a 54% increase in our cost of sales from Q3 last year, primarily driven by higher…

RD expenses for the quarter were $583 million, down 27% from last year, driven by completion and wind down of studies in our infectious disease portfolio, as well as efficiency gains across the organization. SGA expenses for the quarter were $282 million, a 5% increase year over year. We continue to maintain cost discipline across the organization while investing for growth. ?Our income tax provision was immaterial in both periods.

Net income for the quarter was $162 million, an improvement of $362 million compared to last
?year. Diluted earnings per share was $38, compared to a loss per share of 51 cents last year. ?We ended the quarter with cash and investments of $8 billion up from $6.9 billion at the end of the second quarter. ?The increase was primarily driven by $2.6 billion of net proceeds from our convertible note issuance and capped call transaction, partially offset by a $950 million litigation settlement payment, as well as the seasonal impact to working capital.

Passages & reports (10)
  • RD expenses for the quarter were $583 million, down 27% from last year, driven by completi…
  • increase year over year. We continue to maintain cost discipline across the organization w…
  • Our
  • income tax provision was immaterial in both periods. Net income for the quarter was $162 m…
  • year.
  • Diluted earnings per share was $38, compared to a loss per share of 51 cents last year.
  • We
  • ended the quarter with cash and investments of $8 billion up from $6.9 billion at the end …
  • The
  • increase was primarily driven by $2.6 billion of net proceeds from our convertible note is…

turn to our financial framework for 2026. For total revenue, as I mentioned in my earlier remarks, we are improving our revenue outlook to a range of 15 to 25% growth, which exceeds our prior framework of up to 10% growth. Cost of sales is unchanged at $1.7 billion, which includes $0.9 billion of expense related to the previously announced litigation settlement charge. ?We are lowering our RD expense by $200 million to $2.7 billion ?due to further window of studies and continued operational efficiencies.

SGNA expenses are still expected to be approximately $1 billion, flat versus the prior year. Similar to last year, we expect higher SGA expenses in the fourth quarter, primarily due to commercial related activity. In aggregate,
excluding the $0.9 billion litigation charge, we are expecting total gap operating expenses of $4.5 billion and $3.8 billion of cash costs, which exclude stock-based compensation, depreciation, and amortization.

Each reflect a $200 million improvement compared to our previous framework.
?We expect tax taxes to be negligible in 2026, and we are lowering our capital expenditure estimate to $200 million from our previous range of $200 to $300 million. Cash and investments are now projected to be eight be between $8.1 and $8.3 billion at the end of 2026, excluding the $2.6 billion net proceeds from the convertible note and cap call transaction, our cash projection would be $5.5 billion to $5.7 billion, which is an improvement from our previous framework of $4.7 to $5.2 billion. ?

The
increase in our cash projection is due to our improved revenue outlook and reductions in both our cash cost and capex projections. ?Our cash cost framework does not assume any additional drawdown from our remaining $0.9 billion undrawn credit facilities. With that, I will now turn the call over to Steven.

Passages & reports (14)
  • turn to our financial framework for 2026. For total revenue, as I mentioned in my earlier …
  • of expense related to the previously announced litigation settlement charge.
  • We
  • are lowering our RD expense by $200 million to $2.7 billion
  • due
  • to further window of studies and continued operational efficiencies. SGNA expenses are sti…
  • excluding the $0.9 billion litigation charge, we are expecting total gap operating expense…
  • We
  • expect tax taxes to be negligible in 2026, and we are lowering our capital expenditure est…
  • excluding the $2.6 billion net proceeds from the convertible note and cap call transaction…
  • The
  • increase in our cash projection is due to our improved revenue outlook and reductions in b…
  • Our
  • cash cost framework does not assume any additional drawdown from our remaining $0.9 billio…

Speaker unclear

?Thank you, Jamie,

Passages & reports (1)
  • Thank you, Jamie,

Speaker 4

Unverified voice label

and good morning or good afternoon, everyone. I'll now take you through our recent business updates. ?As a reminder, slide 12 outlines our multi-year revenue growth strategy, which continues to be anchored in two key drivers: geographic expansion and portfolio expansion through continued pipeline advancement. ?We are building a more diversified portfolio with new opportunities across respiratory vaccines, oncology, and rare diseases, while expanding our commercial footprint in markets around the ?world.

We're making tangible progress against this strategy with several important milestones achieved during the quarter. Starting with M Flusiva, we recently received FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 65 and older in the U.S. In Canada, we
secured approvals for both MFUSIVA and MCOFU, the local brand name for Encombriax for adults aged 60 and older. ?

For
M Next Spike, we saw approvals for the annual strain updates in the United States, Canada, Japan, and Taiwan for the 2026 2027 vaccination season. ?And for MRESVIA, we continue to make progress in the U.S. and international markets. We expanded our international presence with a five-year agreement signed with a local manufacturer in Mexico to support COVID-19 vaccine supply. And finally, in oncology, we presented positive phase three data for antismerin in adjuvant melanoma at the ESMO Presidential Symposium as highlighted earlier.

These milestones demonstrate continued execution against our strategy to drive revenue growth. Turning to our approved infectious disease portfolio, we continue to make progress across our five commercial products. Starting with our COVID
vaccines. ?As I mentioned earlier, M Next Spike received approval for the updated XFG strain for this coming vaccination season in the United States, Canada, Japan, and Taiwan, with additional regulatory reviews and filings underway.

Spike Fax has also received approval for the updated strain in these
markets and also in the European Union. Deliveries of our updated COVID 19 vaccines are now underway globally. Turning to RSV, MRESVIA is approved in 44 countries. We also received published results from a phase 3 study evaluating revaccination with MRESVIA in adults age 60 and older who had previously received a protein based RSV vaccine.

The study demonstrated robust immune responses comparable to those seen following the initial vaccination with MRESVIA, with no new safety concerns identified, highlighting the potential
?for MRESVIA in revaccination. ?A link to the study can be found on this ?slide. For M Flusiva, our seasonal influenza vaccine, we have approvals in the United States and now Canada, with reviews ongoing in the European Union, Australia, and Taiwan.

In the US, the American Academy of Family Physicians has recommended M Flusiva for adults age 65 and older as an enhanced
influenza vaccine. And finally, for M.Combriax, our combination influenza and COVID 19 vaccine, we now have approvals in Europe and Canada. The product remains under review in Japan, the United Kingdom, Australia, and Switzerland, with a decision on filing in the United States subject to further discussion with EFDA.

Turning to U.S. respiratory vaccination trends, overall demand remains strong, as was said before. Through late October, approximately 44.1 million flu, COVID-19, and RSV vaccinations have been administered in the retail and long-term care channels,
a 3% increase over the comparable period last ?year. Flu vaccinations are trending slightly ahead of last year, and COVID-19 vaccinations are trending slightly behind, but momentum in October suggests vaccinations may end up flat year over year in the channel.

These trends demonstrate the healthy demand for seasonal respiratory vaccines in the United States.
Turning to our late-stage infectious disease pipeline and our norovirus vaccine program, mRNA 1403. ?As a reminder, as previously disclosed, the phase three study did not meet the statistical criteria for early success at its interim analysis. Following a review of the program, we have decided not to enroll an additional cohort this coming winter season.

Instead, we are engaging with health authorities to determine the next steps for the
programs. The program and we'll provide further updates following those discussions. With that, I'll I'll now turn the call over to David to review our oncology and rare disease pipeline.

Passages & reports (33)
  • and good morning or good afternoon, everyone. I'll now take you through our recent busines…
  • As
  • a reminder, slide 12 outlines our multi-year revenue growth strategy, which continues to b…
  • We
  • are building a more diversified portfolio with new opportunities across respiratory vaccin…
  • world.
  • We're making tangible progress against this strategy with several important milestones ach…
  • secured approvals for both MFUSIVA and MCOFU, the local brand name for Encombriax for adul…
  • For
  • M Next Spike, we saw approvals for the annual strain updates in the United States, Canada,…
  • And
  • for MRESVIA, we continue to make progress in the U.S. and international markets. We expand…
  • melanoma at the ESMO Presidential Symposium as highlighted earlier. These milestones demon…
  • vaccines.
  • As
  • I mentioned earlier, M Next Spike received approval for the updated XFG strain for this co…
  • markets and also in the European Union. Deliveries of our updated COVID 19 vaccines are no…
  • older who had previously received a protein based RSV vaccine. The study demonstrated robu…
  • for
  • MRESVIA in revaccination.
  • A
  • link to the study can be found on this
  • slide. For
  • M Flusiva, our seasonal influenza vaccine, we have approvals in the United States and now …
  • influenza vaccine. And finally, for M.Combriax, our combination influenza and COVID 19 vac…
  • EFDA. Turning to U.S. respiratory vaccination trends, overall demand remains strong, as wa…
  • a 3% increase over the comparable period last
  • year.
  • Flu vaccinations are trending slightly ahead of last year, and COVID-19 vaccinations are t…
  • Turning to our late-stage infectious disease pipeline and our norovirus vaccine program, m…
  • As
  • a reminder, as previously disclosed, the phase three study did not meet the statistical cr…
  • programs. The program and we'll provide further updates following those discussions. With …

Speaker 3

Thank you, Stephen. Hello, ?everyone. I will review the progress across

Passages & reports (3)
  • Thank you, Stephen. Hello,
  • everyone.
  • I will review the progress across

Speaker unclear

?our

Passages & reports (1)
  • our

Speaker 2

oncology and rare disease pipeline, starting with Intismeran Autogene, ?our individualized cancer therapy, which is being

Passages & reports (3)
  • oncology and rare disease pipeline, starting with Intismeran Autogene,
  • our individualized
  • cancer therapy, which is being

Speaker unclear

?developed in partnership with MERC. Last

Passages & reports (1)
  • developed in partnership with MERC. Last

Speaker 3

month, we presented the positive phase 3 intrapath 001 melanoma results at the Presidential Symposium at ESMO, ?and I'll discuss these in greater detail shortly. ?A link to the ESMA presentation can be found at the bottom of the slide. Beyond melanoma, ?our Entismeran development program continues to advance across multiple tumor types and stages of disease. In non-small

Passages & reports (7)
  • month, we presented the positive phase 3 intrapath 001 melanoma results at the Presidentia…
  • and
  • I'll discuss these in greater detail shortly.
  • A
  • link to the ESMA presentation can be found at the bottom of the slide. Beyond melanoma,
  • our
  • Entismeran development program continues to advance across multiple tumor types and stages…

Speaker 2

cell lung cancer, the adjuvant phase three study is fully enrolled. Two additional phase

Passages & reports (1)
  • cell lung cancer, the adjuvant phase three study is fully enrolled. Two additional phase

Speaker 3

three studies

Passages & reports (1)
  • three studies

Speaker 2

in non-smell lung cancer continue to enroll patients. One, phase three, is in patients who do not have a pathologic complete response following neoadjuvine therapy. And the other phase three is in stage one disease evaluating intismeran both as a monotherapy and in combination in combination with ketruda culex. Phase two studies in

Passages & reports (2)
  • in non-smell lung cancer continue to enroll patients. One, phase three, is in patients who…
  • Phase two studies in

Speaker 0

adjuvant

Passages & reports (1)
  • adjuvant

Speaker 2

renal cell carcinoma and muscle invasive bladder cancer are fully enrolled. Both of these studies are randomized against ketruda and are event driven studies. We continue to enroll phase two clinical studies in non muscle invasive bladder cancer, metastatic melanoma, ?and metastatic squamous non-small cell lung cancer. Phase one studies in pancreatic and

Passages & reports (3)
  • renal cell carcinoma and muscle invasive bladder cancer are fully enrolled. Both of these …
  • and
  • metastatic squamous non-small cell lung cancer. Phase one studies in pancreatic and

Speaker 3

gastric cancer

Passages & reports (1)
  • gastric cancer

Speaker 2

are

Passages & reports (1)
  • are

Speaker 3

fully

Passages & reports (1)
  • fully

Speaker 2

enrolled.

Passages & reports (1)
  • enrolled.

Speaker unclear

?At

Passages & reports (1)
  • At

Speaker 3

ESMO,

Passages & reports (1)
  • ESMO,

Speaker 2

we presented a poster highlighting encouraging translational data from the phase one pancreatic cancer study. Despite the low tumor mutational burden, typically seen in pancreatic cancer,

Passages & reports (1)
  • we presented a poster highlighting encouraging translational data from the phase one pancr…

Speaker unclear

?we were able to

Passages & reports (1)
  • we were able to

Speaker 3

generate neoantigen-specific

Passages & reports (1)
  • generate neoantigen-specific

Speaker unclear

?T

Passages & reports (1)
  • T

Speaker 0

cell responses in

Passages & reports (1)
  • cell responses in

Speaker 2

all 19 evaluable patients. ?A link to the poster is at the bottom of the slide. Now let's review the phase three melanoma results. ?In the intrapath 001 trial, the primary endpoint was relapse-free survival. Intismaran plus Pembrolizomab demonstrated a significant 42% reduction in the risk of recurrence or death compared with Pembrolizomab alone. ?The hazard ratio was 0.58 and p-value below 0.001. ?These remarkable results were observed at the first interim analysis of this large randomized phase 3 trial enrolling more than 1,100 patients with resected stage 2B through 4 melanoma.

At two years, recurrence free survival was 82.2% in the

Passages & reports (9)
  • all 19 evaluable patients.
  • A
  • link to the poster is at the bottom of the slide. Now let's review the phase three melanom…
  • In the
  • intrapath 001 trial, the primary endpoint was relapse-free survival. Intismaran plus Pembr…
  • The
  • hazard ratio was 0.58 and p-value below 0.001.
  • These
  • remarkable results were observed at the first interim analysis of this large randomized ph…

Speaker 0

combination arm compared with 70% for Pemberluzomabalone, representing a 12 percentage point absolute improvement. These results represent two important firsts. The first positive phase three trial for an individualized cancer

Passages & reports (1)
  • combination arm compared with 70% for Pemberluzomabalone, representing a 12 percentage poi…

Speaker 3

vaccine,

Passages & reports (1)
  • vaccine,

Speaker unclear

?and the first positive phase three

Passages & reports (1)
  • and the first positive phase three

Speaker 3

trial demonstrating benefit

Passages & reports (1)
  • trial demonstrating benefit

Speaker unclear

?over anti PD1 therapy in

Passages & reports (1)
  • over anti PD1 therapy in

Speaker 3

adjuvant melanoma.

Passages & reports (1)
  • adjuvant melanoma.

Speaker unclear

?This

Passages & reports (1)
  • This

Speaker 3

is a summary of the phase two results at three different follow ups. That study also tested in Tismeran plus Pembrolizomab

Passages & reports (1)
  • is a summary of the phase two results at three different follow ups. That study also teste…

Speaker unclear

?versus

Passages & reports (1)
  • versus

Speaker 0

Pembrolizomab monotherapy

Passages & reports (1)
  • Pembrolizomab monotherapy

Speaker 2

and also had an RFS

Passages & reports (1)
  • and also had an RFS

Speaker 0

primary endpoint.

Passages & reports (1)
  • primary endpoint.

Speaker 2

What's particularly

Passages & reports (1)
  • What's particularly

Speaker 0

remarkable

Passages & reports (1)
  • remarkable

Speaker 2

is the

Passages & reports (1)
  • is the

Speaker 0

consistency ?between the phase two hazard ratio of 0.56

Passages & reports (3)
  • consistency
  • between the phase two
  • hazard ratio of 0.56

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 2

the phase three hazard ratio

Passages & reports (1)
  • the phase three hazard ratio

Speaker 0

of 0.58 at

Passages & reports (1)
  • of 0.58 at

Speaker 2

the

Passages & reports (1)
  • the

Speaker unclear

?primary

Passages & reports (1)
  • primary

Speaker 0

analyses, where both had similar follow-up. In our phase two study, the RFS hazard ratio improved from 0.56 to 0.51 at three years, and that benefit was maintained through five years of follow-up. We are optimistic about the potential to see similar strengthening of the treatment benefit in phase three as the data matures. This optimism is further supported by sensitivity analyses from the phase three trial.

Passages & reports (2)
  • analyses, where both had similar follow-up. In our phase two study, the RFS hazard ratio i…
  • strengthening of the treatment benefit in phase three as the data matures. This optimism i…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 0

the phase three

Passages & reports (1)
  • the phase three

Speaker 2

trial, we

Passages & reports (1)
  • trial, we

Speaker 0

conducted pre-specified sensitivity

Passages & reports (1)
  • conducted pre-specified sensitivity

Speaker 2

analyses that provide additional insights into the treatment to benefit. One of these analyses evaluated the modified intent to treat or MITT population, which evaluates only patients who received the intended intismeran or placebo injection. Patients were randomized and received temporalismap, but either relapsed or withdrew prior to the first dose ?of intismeran or placebo as planned, were excluded. In other words, while the ITT analysis shows the results of a phase three clinical trial, the MITT analysis, by limiting to patients actually treated with the blinded vaccine shows the true

Passages & reports (4)
  • analyses that provide additional insights into the treatment to benefit. One of these anal…
  • Patients were randomized and received temporalismap, but either relapsed or withdrew prior…
  • of
  • intismeran or placebo as planned, were excluded. In other words, while the ITT analysis sh…

Speaker unclear

?treatment effect of

Passages & reports (1)
  • treatment effect of

Speaker 3

entismeran. In this MITT analysis,

Passages & reports (1)
  • entismeran. In this MITT analysis,

Speaker 0

we observed an even greater treatment benefit

Passages & reports (1)
  • we observed an even greater treatment benefit

Speaker unclear

?with a 49% reduction in the risk of recurrence or death compared with the 42% reduction observed in the primary ITT.

Passages & reports (1)
  • with a 49% reduction in the risk of recurrence or death compared with the 42% reduction ob…

Speaker 3

Notably, ?the hazard ?ratio of 0.51

Passages & reports (5)
  • Notably,
  • the
  • hazard
  • ratio of
  • 0.51

Speaker unclear

?is consistent with what we observed in phase two

Passages & reports (1)
  • is consistent with what we observed in phase two

Speaker 0

at the three and five year follow-ups. ?At two years, the recurrence free survival was 84.2% with the combination compared with 70.4% for pembroly balloon, representing nearly a 14% point absolute improvements.

Passages & reports (3)
  • at the three and five year follow-ups.
  • At
  • two years, the recurrence free survival was 84.2% with the combination compared with 70.4%…

Speaker unclear

?Together,

Passages & reports (1)
  • Together,

Speaker 3

the ITT and MATT

Passages & reports (1)
  • the ITT and MATT

Speaker unclear

?analyses

Passages & reports (1)
  • analyses

Speaker 0

reinforced the

Passages & reports (1)
  • reinforced the

Speaker unclear

?strength and consistency of the efficacy between phase

Passages & reports (1)
  • strength and consistency of the efficacy between phase

Speaker 2

three and

Passages & reports (1)
  • three and

Speaker unclear

?phase two. The degree of benefit for the combination over pembrolyzimab

Passages & reports (1)
  • phase two. The degree of benefit for the combination over pembrolyzimab

Speaker 3

monotherapy, which itself is a great drug, is one reason that I

Passages & reports (1)
  • monotherapy, which itself is a great drug, is one reason that I

Speaker 2

am optimistic

Passages & reports (1)
  • am optimistic

Speaker unclear

?intismeran will work

Passages & reports (1)
  • intismeran will work

Speaker 0

in ?other tumor types.

Passages & reports (3)
  • in
  • other
  • tumor types.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

combination of intismeran plus pembrolyzimab ?was generally well

Passages & reports (3)
  • combination of intismeran plus pembrolyzimab
  • was generally
  • well

Speaker 3

tolerated, with findings consistent

Passages & reports (1)
  • tolerated, with findings consistent

Speaker unclear

?with the known safety profiles of the individual therapies. Adding intismeran did not

Passages & reports (1)
  • with the known safety profiles of the individual therapies. Adding intismeran did not

Speaker 2

meaningfully increase pembrolyzimab associated adverse events of interest, which occurred in 36% of patients receiving the combination compared to 35% of patients receiving pembroly.

Passages & reports (1)
  • meaningfully increase pembrolyzimab associated adverse events of interest, which occurred …

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 2

adverse events associated with intismeran were also consistent with its expected safety profile.

Passages & reports (1)
  • adverse events associated with intismeran were also consistent with its expected safety pr…

Speaker 0

The most common

Passages & reports (1)
  • The most common

Speaker 2

adverse events in the combination arm were pyrexia, injection sight pain, and fatigue. These events were generally low grade, transient, and were managed with standard supportive care. These findings are encouraging,

Passages & reports (1)
  • adverse events in the combination arm were pyrexia, injection sight pain, and fatigue. The…

Speaker unclear

?particularly

Passages & reports (1)
  • particularly

Speaker 0

in the context of the significant improvement ?in re in relapse-free survival demonstrated in the study. I'll now turn to our broader oncology portfolio. Outside of Entosmoran, we continue to advance a diversified portfolio of oncology

Passages & reports (3)
  • in the context of the significant improvement
  • in re
  • in relapse-free survival demonstrated in the study. I'll now turn to our broader oncology …

Speaker 2

programs across cancer antigen therapies, T cell engagers, and cell therapy enhancement.

Passages & reports (1)
  • programs across cancer antigen therapies, T cell engagers, and cell therapy enhancement.

Speaker 0

Starting with mRNA

Passages & reports (1)
  • Starting with mRNA

Speaker 2

4359, our cancer antigen therapy, we have an ongoing phase two study in first-line

Passages & reports (1)
  • 4359, our cancer antigen therapy, we have an ongoing phase two study in first-line

Speaker 0

metastatic melanoma, secondline or later metastatic

Passages & reports (1)
  • metastatic melanoma, secondline or later metastatic

Speaker 2

melanoma, and first line metastatic non-small cell lung cancer. Our mRNA 4194 program is progressing in a phase 12 study in Lynch syndrome with phase one dose escalation ongoing. We also continue to advance mRNA 4106 and mRNA 4200 with phase one studies dosing patients currently. Turning to our T-cell engager program, mRNA 2808 is in a phase one study in multiple myeloma. ?The initial clinical results have been ?selected for an oral presentation ?at the upcoming ASH annual ?meeting in December, and we look forward to presenting the data and advancing this program.

Finally,
?in collaboration with AMADICs, we continue dosing in the phase one study of our cell therapy enhancer, mRNA

Passages & reports (12)
  • melanoma, and first line metastatic non-small cell lung cancer. Our mRNA 4194 program is p…
  • 4200 with phase one studies dosing patients currently. Turning to our T-cell engager progr…
  • The
  • initial clinical results have been
  • selected
  • for an oral presentation
  • at the upcoming
  • ASH annual
  • meeting in
  • December, and we look forward to presenting the data and advancing this program. Finally,
  • in
  • collaboration with AMADICs, we continue dosing in the phase one study of our cell therapy …

Speaker 0

4203,

Passages & reports (1)
  • 4203,

Speaker unclear

?in

Passages & reports (1)
  • in

Speaker 2

combination with NZU cell. Across these programs,

Passages & reports (1)
  • combination with NZU cell. Across these programs,

Speaker unclear

?we're

Passages & reports (1)
  • we're

Speaker 3

evaluating several distinct therapeutic approaches and continue to generate clinical evidence to guide further development. Turning briefly to our rare

Passages & reports (1)
  • evaluating several distinct therapeutic approaches and continue to generate clinical evide…

Speaker unclear

?disease

Passages & reports (1)
  • disease

Speaker 0

pipeline, our registrational trial in propionic acidemia, or PA, is on track, and we look forward to the results later this year. ?For methylmalonic acidemia,

Passages & reports (3)
  • pipeline, our registrational trial in propionic acidemia, or PA, is on track, and we look …
  • For
  • methylmalonic acidemia,

Speaker 2

or MMA, we've deferred the decision to initiate a pivotal trial until after the PA readout. With that, I'll hand

Passages & reports (1)
  • or MMA, we've deferred the decision to initiate a pivotal trial until after the PA readout…

Speaker 3

the call back to Stefan.

Passages & reports (1)
  • the call back to Stefan.

Speaker 2

Thank you, David, Stephen and Jamie. Looking ahead, we continue to see important value drivers across our commercial business, financial performance, and pipeline. ?We have raised our full year 2026 revenue growth expectations to between 15 and 20% growth, exceeding our previous revenue growth expectation of up to 10%.

Passages & reports (3)
  • Thank you, David, Stephen and Jamie. Looking ahead, we continue to see important value dri…
  • We
  • have raised our full year 2026 revenue growth expectations to between 15 and 20% growth, e…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 2

also continue to execute with financial discipline, lowering our adjusted cash cost target by another two hundred million dollars to approximately three point eight billion for fiscal year twenty six. ?And we have raised our year cash and investment outlook to between eight point one and eight point three billion. ?On the commercial side, we continue to pursue additional regulatory approvals to expand the global reach of our respiratory vaccine portfolio.

Turning to our pipeline, twenty 2026 has been a landmark year for oncology, highlighted by our positive phase 3 melanoma result for intismeran, and
the presentation of encouraging early pancreatic cancer data at ESMO. Looking ahead, key milestone includes our event-driven phase 2, renal cancer without, ?the intismeran BLA submission, ?the presentation of MRNA 2808 at ASH, ?and a registration redoubt in propenic acidemia or PA, our most advanced rare genetic disease program.

Our priorities remain clear. Grow our commercial business, maintain financial discipline, and advance our pipeline toward important clinical and regulatory milestones. I'm very
proud of what our team have accomplished this year and excited about the opportunities ahead for Moderna.

Passages & reports (13)
  • also continue to execute with financial discipline, lowering our adjusted cash cost target…
  • And
  • we have raised our year cash and investment outlook to between eight point one and eight p…
  • On
  • the commercial side, we continue to pursue additional regulatory approvals to expand the g…
  • the presentation of encouraging early pancreatic cancer data at ESMO. Looking ahead, key m…
  • the
  • intismeran BLA submission,
  • the
  • presentation of MRNA 2808 at ASH,
  • and
  • a registration redoubt in propenic acidemia or PA, our most advanced rare genetic disease …
  • proud of what our team have accomplished this year and excited about the opportunities ahe…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 2

look forward to hosting the investment community next week at our upcoming analysis day on November 12th. The event will be held in person ?at our Inti Marine Manufacturing Site ?in Marlborough, Massachusetts, where attendees will have also the opportunity to tour the site. ?A webcast of our presentation will be available for those joining remotely. ?I want to close by thanking our teams around the world for their dedication and execution.

This has been an important year for Moderna, and our progress reinforces what we can accomplish when we combine bold science with disciplined execution. Our
platform is delivering fiber-approved infectious vaccines around the world, positive phase 3 for NT's MERAN, ?and a new modality with MRNA 2808 proof of concept in multiple myoma for T cell engagers. Our mission remains at the heart of everything we ?do: to deliver the greatest possible impact to through MRNA medicine.

With that, we'll be happy to take your questions.

Passages & reports (14)
  • look forward to hosting the investment community next week at our upcoming analysis day on…
  • at
  • our Inti Marine Manufacturing Site
  • in
  • Marlborough, Massachusetts, where attendees will have also the opportunity to tour the sit…
  • A
  • webcast of our presentation will be available for those joining remotely.
  • I
  • want to close by thanking our teams around the world for their dedication and execution. T…
  • platform is delivering fiber-approved infectious vaccines around the world, positive phase…
  • and
  • a new modality with MRNA 2808 proof of concept in multiple myoma for T cell engagers. Our …
  • do:
  • to deliver the greatest possible impact to through MRNA medicine. With that, we'll be happ…

Speaker 0

Thank you, ladies and gentlemen. If you have a question or a comment at this time, please press star one one on your telephone. If your question has been answered, you wish to move yourself from the queue, please press star one one again. We'll pause for a moment while we compile our QA roster.

Passages & reports (1)
  • Thank you, ladies and gentlemen. If you have a question or a comment at this time, please …

Questions & answers

Speaker 0

Our first question comes from Salvine Richter with Goldman Sachs. Your line is open.

Passages & reports (1)
  • Our first question comes from Salvine Richter with Goldman Sachs. Your line is open.

Speaker unclear

?Thank you,

Passages & reports (1)
  • Thank you,

Speaker 5

Unverified voice label

good morning. Um two questions for me. One is could you frame c your confidence into the interim data in renal cell carcinoma, particularly as we think about the statistical plan with regard to number of events that needs to be hit around that interim? And then if you could also touch on the fact that there have been some questions and the contribution of the LNP to immunogenicity with regard to the melanoma trial, and um maybe just help frame that for us as well.

Thank

Passages & reports (2)
  • good morning. Um two questions for me. One is could you frame c your confidence into the i…
  • that there have been some questions and the contribution of the LNP to immunogenicity with…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 3

Selvine. Thank you very much for the question. In terms of the uh timing,

Passages & reports (1)
  • Selvine. Thank you very much for the question. In terms of the uh timing,

Speaker 2

it's event driven for the RCC trial, so it could

Passages & reports (1)
  • it's event driven for the RCC trial, so it could

Speaker unclear

?be

Passages & reports (1)
  • be

Speaker 3

end of this year or early next year. In terms of the confidence for that, why I'm confident, I would say probably a couple of reasons. First is that we know that RCC is an anti PD1 sensitive tumor. Anti PD1s work by T cells, by reactivating T cells. We work

Passages & reports (1)
  • end of this year or early next year. In terms of the confidence for that, why I'm confiden…

Speaker 2

by generating novel T cells. ?And so it's a T ?cell sensitive disease, and so that's confidence number one. Confidence number ?two derives from the fact that ?in our phase ?two trial, we saw efficacy ?in the melanoma population at both that ?was equivalent for high TMB and for low TMB patients. And if ?you overlap the low

Passages & reports (17)
  • by generating novel T cells.
  • And
  • so it's a T
  • cell sensitive
  • disease, and so that's confidence number one. Confidence number
  • two
  • derives from the fact that
  • in our
  • phase
  • two trial,
  • we saw efficacy
  • in the
  • melanoma population at both that
  • was
  • equivalent for high TMB and for low TMB patients. And if
  • you
  • overlap the low

Speaker 3

TMB spectrum in the melanoma, it actually does overlap with RCC. And then finally, the treatment benefits that we saw in the primary analysis has ratio 0.58 versus pembrolyzomab alone. That was the same treatment effect that Pembrolizimab alone saw versus placebo in their keynote 54. And then we know Cetruda went on to be positive

Passages & reports (2)
  • TMB spectrum in the melanoma, it actually does overlap with RCC. And then finally, the tre…
  • 54. And then we know Cetruda went on to be positive

Speaker 2

in

Passages & reports (1)
  • in

Speaker 3

RCC as well. So those are the reasons why I

Passages & reports (1)
  • RCC as well. So those are the reasons why I

Speaker 2

have

Passages & reports (1)
  • have

Speaker 3

confidence or belief that we are likely potentially to have a positive result.

Passages & reports (1)
  • confidence or belief that we are likely potentially to have a positive result.

Speaker 2

I don't say anything more about the statistical analysis plan. In terms of the LNP immunogenicity question, this is a question that's been going on for a while. Just um ?to orient everyone, it came up a few years ago when MD Anderson published a retrospective analysis. Um, ?and it wasn't a randomized trial, it was just observation, and they

Passages & reports (5)
  • I don't say anything more about the statistical analysis plan. In terms of the LNP immunog…
  • to
  • orient everyone, it came up a few years ago when MD Anderson published a retrospective ana…
  • and it
  • wasn't a randomized trial, it was just observation, and they

Speaker 3

suggested that patients who got the an mRNA LMP vaccine had better outcomes to immunotherapy. That has that uh data from MD Anderson has subsequently been repeated and not being repeated by different groups. And in fact, most recently, Memorial Sloan Kettering, which is the other large cancer center in the US, came out with their own analysis showing that actually there was no treatment effect by the addition of uh of mRNA LNP.

So I don't think that um this that answer is clear. I don't think the evidence is strong enough to um claim it. And I don't think LNP

Passages & reports (2)
  • suggested that patients who got the an mRNA LMP vaccine had better outcomes to immunothera…
  • came out with their own analysis showing that actually there was no treatment effect by th…

Speaker unclear

?can

Passages & reports (1)
  • can

Speaker 2

generate such an

Passages & reports (1)
  • generate such an

Speaker 3

incredibly strong ?hazard ratio in the adjuvant setting.

Passages & reports (3)
  • incredibly strong
  • hazard
  • ratio in the adjuvant setting.

Speaker 0

Thank you. One moment for our next

Passages & reports (1)
  • Thank you. One moment for our next

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Terrence Flynn with Morgan Stanley. Your line is

Passages & reports (1)
  • next question comes from Terrence Flynn with Morgan Stanley. Your line is

Speaker unclear

?open.

Passages & reports (1)
  • open.

Speaker 0

Great.

Passages & reports (1)
  • Great.

Speaker unclear

?Thanks so much for

Passages & reports (1)
  • Thanks so much for

Speaker 3

taking the question. I was just wondering, I know you're not going to guide on price at this point for INT, but was just wondering if you could talk through some of the inputs that you and Merck are considering as you think about

Passages & reports (1)
  • taking the question. I was just wondering, I know you're not going to guide on price at th…

Speaker 6

Unverified voice label

pricing that therapy. And then the second question I had is just on the phase two RCC study, if those data are positive, do you think that can support a registration in that setting? Thank

Passages & reports (1)
  • pricing that therapy. And then the second question I had is just on the phase two RCC stud…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 4

Thank you. Look, I uh uh this is Steven. I'll take the first part of it on price and then I think hand it over to David. Um the uh on price, look it's premature at this point. Um we're working on uh getting a submission done this year and obviously working towards approval. Um we will always um look to price our products to represent the value they create in healthcare systems and obviously we're thrilled by the data um but it is um premature at this point to say anything more.

And we'll work closely with Merck on that process.

Passages & reports (2)
  • Thank you. Look, I uh uh this is Steven. I'll take the first part of it on price and then …
  • we will always um look to price our products to represent the value they create in healthc…

Speaker unclear

?Steve, uh thanks, Steven. Um Terrence, in regards to

Passages & reports (1)
  • Steve, uh thanks, Steven. Um Terrence, in regards to

Speaker 2

your second

Passages & reports (1)
  • your second

Speaker unclear

?question, look, it's it's a it's a pretty

Passages & reports (1)
  • question, look, it's it's a it's a pretty

Speaker 3

large randomized, uh

Passages & reports (1)
  • large randomized, uh

Speaker 2

well-controlled phase two with 282 patients. Um but it is um it is a phase two. So uh ?at a base case, I would say it can be practice informing, um especially with compendium listing if it's positive. In an upside, if the results are very strong, I think we can consider taking it to FDA, but it will be data dependent.

Passages & reports (3)
  • well-controlled phase two with 282 patients. Um but it is um it is a phase two. So uh
  • at
  • a base case, I would say it can be practice informing, um especially with compendium listi…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. One moment for our next

Passages & reports (1)
  • you. One moment for our next

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Ellie Merle with Barclays. Your line is open.

Passages & reports (1)
  • next question comes from Ellie Merle with Barclays. Your line is open.

Speaker 5

Hey guys, thanks so much for taking the question.

Passages & reports (1)
  • Hey guys, thanks so much for taking the question.

Speaker 7

Unverified voice label

On the back of the pancreatic data at ESMO, can you elaborate on how you're thinking about potential next development steps here? Would you study in combo with PD1, with chemo, or both? And then just a quick one on RCC. If the study is not successful on the first interim, is that something you disclose if it moves on to additional analyses? Thanks.

Passages & reports (2)
  • On the back of the pancreatic data at ESMO, can you elaborate on how you're thinking about…
  • disclose if it moves on to additional analyses? Thanks.

Speaker 3

Ellie, so with regard to the PDAC, look, the the good news is that in this low TMB tumor, we were able to generate

Passages & reports (1)
  • Ellie, so with regard to the PDAC, look, the the good news is that in this low TMB tumor, …

Speaker 2

um cassettes and from from the patients. And in all of the evaluable patients, we were able to see uh T cell

Passages & reports (1)
  • um cassettes and from from the patients. And in all of the evaluable patients, we were abl…

Speaker unclear

?reacting to those neoantigens. So I think that's a really good sign.

Passages & reports (1)
  • reacting to those neoantigens. So I think that's a really good sign.

Speaker 2

And we ?did it in combination with the standard of care, which is fulfillinox. So it informed us that it can safely be given with chemotherapy, which I think

Passages & reports (3)
  • And we
  • did
  • it in combination with the standard of care, which is fulfillinox. So it informed us that …

Speaker 3

we um probably assumed it could, and that we can still generate uh T cell reactivity in the face of um ?of the

Passages & reports (3)
  • we um probably assumed it could, and that we can still generate uh T cell reactivity in th…
  • of
  • the

Speaker 2

addition of chemotherapy. ?I think for next steps, we're actively discussing that with uh with Merck right now. I think

Passages & reports (3)
  • addition of chemotherapy.
  • I
  • think for next steps, we're actively discussing that with uh with Merck right now. I think

Speaker 3

um it could be in the same regimen that we studied, it could be in combination

Passages & reports (1)
  • um it could be in the same regimen that we studied, it could be in combination

Speaker unclear

?with the RAS

Passages & reports (1)
  • with the RAS

Speaker 2

inhibitor. I think we need to do a little more thinking about that because the standard of care is changing. And uh ?um in terms of the disclosure, I don't think we've uh decided yet uh how we're

Passages & reports (3)
  • inhibitor. I think we need to do a little more thinking about that because the standard of…
  • um
  • in terms of the disclosure, I don't think we've uh decided yet uh how we're

Speaker unclear

?gonna handle that.

Passages & reports (1)
  • gonna handle that.

Speaker 0

Thank you. One moment for our next question.

Passages & reports (1)
  • Thank you. One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Edward Tenhoff with Piper Stanley. Your line is open. ?Great. Thank you very much. And congrats on all

Passages & reports (3)
  • next question comes from Edward Tenhoff with Piper Stanley. Your line is open.
  • Great. Thank you
  • very much. And congrats on all

Speaker unclear

?the progress.

Passages & reports (1)
  • the progress.

Speaker 0

My

Passages & reports (1)
  • My

Speaker 6

questions are just on the BLA for Antismer ?and what still has to happen and are you working collaboratively with Merck on that? Are they driving the bus? And then just kind of get a sense for when we might get data from the lung cancer studies. And maybe you can kind of break out sort of how those Thanks so

Passages & reports (4)
  • questions are just on the BLA for Antismer
  • and
  • what still has to happen and are you working collaboratively with Merck on that? Are they …
  • Thanks so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 4

Ted, I'll uh Stephen, I'll take the first part of that and then hand over to David to speak through the lung cancer ?work. Um so we're we're working uh intensely with our partner Merck, as um as we said earlier, ?as Stefan mentioned a moment ago, um we are working to make sure that submission with the BLA happens this year. Uh and you know if everything goes well, um, as has been said before, we would hope to see approval next year.

Um there are lots of steps as you know pulling those things together,
including getting ready for pre-approval inspections and everything. And I can assure you working around the clock to make sure that not only the submission happens on time, but the review is facilitated with the FDA because our goal here ultimately is approval. But working very closely with Merck together on that as we speak.

Passages & reports (6)
  • Ted, I'll uh Stephen, I'll take the first part of that and then hand over to David to spea…
  • work.
  • Um so we're we're working uh intensely with our partner Merck, as um as we said earlier,
  • as
  • Stefan mentioned a moment ago, um we are working to make sure that submission with the BLA…
  • including getting ready for pre-approval inspections and everything. And I can assure you …

David?

Passages & reports (1)
  • David?

Speaker unclear

?Thanks, David. The Lung Cancer

Passages & reports (1)
  • Thanks, David. The Lung Cancer

Speaker 3

Adjuvant program is actually really um comprehensive. We announced that we have just about completed, we have

Passages & reports (1)
  • Adjuvant program is actually really um comprehensive. We announced that we have just about…

Speaker unclear

?completed enrollment

Passages & reports (1)
  • completed enrollment

Speaker 2

in the interismand

Passages & reports (1)
  • in the interismand

Speaker 3

zero

Passages & reports (1)
  • zero

Speaker unclear

?in

Passages & reports (1)
  • in

Speaker 2

the I in the

Passages & reports (1)
  • the I in the

Speaker 3

intrapath

Passages & reports (1)
  • intrapath

Speaker 2

002, which is adjuvant after chemotherapy with no neoadjuvant therapy. In fact, this was the fastest enrolling, uh, one of the Merck's fastest enrolling trials, just to give you a sense of the excitement. We are still ongoing enrollment in enrollment in uh patients who had ?who had neoadjuvant Pembroke chemo and and did not have pathologic complete response. That's still enrolling, so it's too soon to know what's going to happen in terms of timing there.

And then we have the really exciting high risk stage one lung cancer phase three, where for the first time we're testing intismeran monotherapy and
one-of-the-arms also still enrolling there. In terms of um readouts and timings, I think it's a little too soon. Uh we just finished to predict, it's we just finished enrolling, and so now we need to start monitoring events and and then we'll have a better idea about timing.

Passages & reports (4)
  • 002, which is adjuvant after chemotherapy with no neoadjuvant therapy. In fact, this was t…
  • who
  • had neoadjuvant Pembroke chemo and and did not have pathologic complete response. That's s…
  • one-of-the-arms also still enrolling there. In terms of um readouts and timings, I think i…

Speaker 6

Thanks, David.

Passages & reports (1)
  • Thanks, David.

Speaker 0

One moment for our next

Passages & reports (1)
  • One moment for our next

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Alex Turnerhan with the Bank of America. Your line is open.

Passages & reports (1)
  • next question comes from Alex Turnerhan with the Bank of America. Your line is open.

Speaker unclear

?Hey guys, uh thanks for

Passages & reports (1)
  • Hey guys, uh thanks for

Speaker 2

taking our questions. Um two two from us, one on twenty eight oh eight and one financial question. ?Um looking forward ?to to the data at Ash, ?I guess what will

Passages & reports (7)
  • taking our questions. Um two two from us, one on twenty eight oh eight and one financial q…
  • Um
  • looking forward
  • to to the
  • data at Ash,
  • I guess
  • what will

Speaker unclear

?the update add beyond the the

Passages & reports (1)
  • the update add beyond the the

Speaker 2

first eleven response available

Passages & reports (1)
  • first eleven response available

Speaker unclear

?um patients in terms of you know

Passages & reports (1)
  • um patients in terms of you know

Speaker 2

more patients, higher dose, durability,

Passages & reports (1)
  • more patients, higher dose, durability,

Speaker unclear

?and I guess

Passages & reports (1)
  • and I guess

Speaker 4

how does this program maybe reflect the broader oncology opportunity you see for the platform. And quickly on your 2026

Passages & reports (1)
  • how does this program maybe reflect the broader oncology opportunity you see for the platf…

Speaker 2

growth

Passages & reports (1)
  • growth

Speaker 4

guidance increase, how much of ?this came from timing? Meaning deliveries moved into 2026. And does any of it, I guess, pull revenue forward from 2027? Thanks.

Passages & reports (3)
  • guidance increase, how much of
  • this came from
  • timing? Meaning deliveries moved into 2026. And does any of it, I guess, pull revenue forw…

Speaker 2

Alex, with regard to your program, thanks for highlighting 2808. It is actually one of the exciting early stage programs we have.

Passages & reports (1)
  • Alex, with regard to your program, thanks for highlighting 2808. It is actually one of the…

Speaker 2

is the first time ever ?that three antigens have been targeted, and that's why we're excited this is going to be an RL presentation. The data cut is later for the RL than it was for the abstract, so you can expect more patients, longer follow-up, and evaluation of what of um whether we can get a deeper response and activity in patients who had prior BCMA ?and GPCR5D.

In terms of the broader implications, this is testing a hypothesis we have that one of the benefits of our platform is that we can multiplex. And so we're multiplexing here against different tumor antigens
?in the form of three T cell engagers, but it can also show that we can multiplex on the other side, you know, going after different T cell stimulation approaches as well.

So the fact that this works shows that uh we can multiplex, we can generate systemic proteins
?to treat cancer, and I think that's a very important proof of principle.

Passages & reports (10)
  • is the first time ever
  • that
  • three antigens have been targeted, and that's why we're excited this is going to be an RL …
  • in patients who had prior BCMA
  • and
  • GPCR5D. In terms of the broader implications, this is testing a hypothesis we have that on…
  • in
  • the form of three T cell engagers, but it can also show that we can multiplex on the other…
  • to
  • treat cancer, and I think that's a very important proof of principle.

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 3

David. Yeah, and Alex, thanks for the question. So ?I we're encouraged that this is really broad base growth

Passages & reports (3)
  • David. Yeah, and Alex, thanks for the question. So
  • I
  • we're encouraged that this is really broad base growth

Speaker 2

this year. It is both US and international. ?And I just go back to some of my prepared remarks, which was we came into the year with two pro key growth drivers, M Next Spike, that is performing extremely well in the US. ?But in addition to that, in the US, vaccination rates are stable, which Steven walked through on his chart. Internationally, we came in thinking about the strategic partnerships, and those have all performed uh extremely well also.

Passages & reports (5)
  • this year. It is both US and international.
  • And
  • I just go back to some of my prepared remarks, which was we came into the year with two pr…
  • But
  • in addition to that, in the US, vaccination rates are stable, which Steven walked through …

Speaker unclear

?So

Passages & reports (1)
  • So

Speaker 3

when ?we look to

Passages & reports (3)
  • when
  • we
  • look to

Speaker 2

2027,

Passages & reports (1)
  • 2027,

Speaker 3

I go back to what Steven presented in terms of there are still four growth drivers out there. Flu is relatively immaterial right now for us in the in 2026

Passages & reports (1)
  • I go back to what Steven presented in terms of there are still four growth drivers out the…

Speaker 2

and we expect to grow next year. Europe

Passages & reports (1)
  • and we expect to grow next year. Europe

Speaker unclear

?opens up for us,

Passages & reports (1)
  • opens up for us,

Speaker 3

Latin America partnerships,

Passages & reports (1)
  • Latin America partnerships,

Speaker 2

hopefully we will have INT approved. So so we're quite encouraged.

Passages & reports (1)
  • hopefully we will have INT approved. So so we're quite encouraged.

Speaker 3

So

Passages & reports (1)
  • So

Speaker 2

again,

Passages & reports (1)
  • again,

Speaker 3

I was a broad-based growth in 2026 and the two

Passages & reports (1)
  • I was a broad-based growth in 2026 and the two

Speaker 2

primary growth drivers are going well for us.

Passages & reports (1)
  • primary growth drivers are going well for us.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

One moment for our next question.

Passages & reports (1)
  • One moment for our next question.

Speaker 0

Our next question comes from Miles Minter with William Blair. Your line is open.

Passages & reports (1)
  • Our next question comes from Miles Minter with William Blair. Your line is open.

Speaker unclear

?Hey, uh, congrats on the quarter and and all of the updates

Passages & reports (1)
  • Hey, uh, congrats on the quarter and and all of the updates

Speaker 3

with Interpatha

Passages & reports (1)
  • with Interpatha

Speaker 4

001. I actually had just a question

Passages & reports (1)
  • 001. I actually had just a question

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 3

neurovirus. Uh I think at your last quarterly update you you indicated you were going to enroll another cohort. Now you're not, and you're going to the regulators just wondering, you know, what changed there and what you're hoping to get out of those regulatory discussions.

Passages & reports (1)
  • neurovirus. Uh I think at your last quarterly update you you indicated you were going to e…

Speaker 4

Thanks very much.

Passages & reports (1)
  • Thanks very much.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 4

Miles, thank you for the question. Um, at this point, uh, I don't have much more to say than we already did. Uh you're correct. Um, we did not meet the criteria for early success, um, and we were going forward with a cohort initially. But as we review the program, ?uh, we think the most appropriate next step is not to go forward with that cohort, but instead consult with regulators.

Um and at this point it's premature for me to guide any further on that. Um, but once we've had those discussions with them about the potential next steps of the program, we'll be able
to provide an update more broadly. So for now, um we'll have to have those conversations before I can offer anything

Passages & reports (4)
  • Miles, thank you for the question. Um, at this point, uh, I don't have much more to say th…
  • uh,
  • we think the most appropriate next step is not to go forward with that cohort, but instead…
  • to provide an update more broadly. So for now, um we'll have to have those conversations b…

Speaker unclear

?more. No all right. Thanks.

Passages & reports (1)
  • more. No all right. Thanks.

Speaker 0

One moment for our next question.

Passages & reports (1)
  • One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Tyler Van Buren with TD Cowan. Your line is open. ?Hey guys uh thanks so much for taking the questions and congrats on the quarterly results. Um ?so the melanoma

Passages & reports (5)
  • next question comes from Tyler Van Buren with TD Cowan. Your line is open.
  • Hey
  • guys uh thanks so much for taking the questions and congrats on the quarterly results. Um
  • so
  • the melanoma

Speaker unclear

?INT results are clearly stellar uh but regarding the next readout in

Passages & reports (1)
  • INT results are clearly stellar uh but regarding the next readout in

Speaker 6

RCC

Passages & reports (1)
  • RCC

Speaker unclear

?some KOLs have brought up research suggesting

Passages & reports (1)
  • some KOLs have brought up research suggesting

Speaker 2

that RCC immunogenicity ?may be driven in

Passages & reports (3)
  • that RCC immunogenicity
  • may be driven
  • in

Speaker unclear

?part by HIF-regulated endogenous retroviral

Passages & reports (1)
  • part by HIF-regulated endogenous retroviral

Speaker 6

elements. ?So can the current INT antigen selection ?process identify and incorporate those types ?of non-canonical antigens ?and how might ?that impact the probability of success?

Passages & reports (11)
  • elements.
  • So can
  • the current INT antigen selection
  • process identify and incorporate
  • those types
  • of
  • non-canonical antigens
  • and how
  • might
  • that
  • impact the probability of success?

Speaker 2

Hi, Tyler. Thanks for the question. Yeah,

Passages & reports (1)
  • Hi, Tyler. Thanks for the question. Yeah,

Speaker unclear

?it's it's an

Passages & reports (1)
  • it's it's an

Speaker 3

interesting hypothesis that um has been put out there. I think it's

Passages & reports (1)
  • interesting hypothesis that um has been put out there. I think it's

Speaker 2

hypothesis and it's a question whether endogenous retrovirals play a role or not. What I do

Passages & reports (1)
  • hypothesis and it's a question whether endogenous retrovirals play a role or not. What I d…

Speaker 3

know is that um our our uh algorithm does include

Passages & reports (1)
  • know is that um our our uh algorithm does include

Speaker 2

insertion deletions

Passages & reports (1)
  • insertion deletions

Speaker 3

indels which are actually um strongly

Passages & reports (1)
  • indels which are actually um strongly

Speaker 2

demonstrated

Passages & reports (1)
  • demonstrated

Speaker 3

to be important um in uh in

Passages & reports (1)
  • to be important um in uh in

Speaker 2

RCC

Passages & reports (1)
  • RCC

Speaker 3

as ?well as

Passages & reports (3)
  • as
  • well
  • as

Speaker 2

neoantigens and single point neoantigens that ?is and then I'll also point you out to uh a a publication recently from Dana Farber where they did their own personalized cancer vaccine and were able to identify sufficient neoantigens without the addition of uh endogenous retrovirals. So the ERVs are interesting, they're speculative, and I think more research needs to be made before we include ?them.

Great. Thanks, David.

Passages & reports (6)
  • neoantigens and single point neoantigens that
  • is
  • and then I'll also point you out to uh a a publication recently from Dana Farber where the…
  • we include
  • them.
  • Great. Thanks, David.

Speaker 0

One moment for our next

Passages & reports (1)
  • One moment for our next

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Andrew Sai with Jeffrey.

Passages & reports (1)
  • next question comes from Andrew Sai with Jeffrey.

Speaker 6

Hi, good morning. Thanks for the updates. As we think about the BLA submission for melanoma with INT, can you talk about whether you would need some kind of special FDA approval on the algorithm side on top of the drug side? And secondly, if the power of AI continues to improve rapidly, can you just maybe talk about why competitors, hypothetically speaking, can't catch ?up to you on the

Passages & reports (4)
  • Hi, good morning. Thanks for the updates. As we think about the BLA submission for melanom…
  • just maybe talk about why competitors, hypothetically speaking, can't catch
  • up
  • to you on the

Speaker unclear

?algorithm side? Why do you think you have a protective moat? Thank you.

Passages & reports (1)
  • algorithm side? Why do you think you have a protective moat? Thank you.

Speaker 4

Great. Thank you for that question. So, first of all, yes, obviously the uh algorithm for selection, in fact the entire front end process for designing an INT for an individual patient is a part of the drug. Um effectively there is software in ?it. Um and that is a proprietary uh feature of our platform, our technology. It's not something um that uh will be readily available.

Um the important question maybe is the one that you the second part of yours, which is then how does that place forward? Um and yeah, we're we're incredibly excited excited by
what we've learned in our clinical trials. And bear in ?mind, you know, the randomized data we have on immunogenicity from the phase two was in ?you know about 150 people, about 100 people who received INT.

There's now been followed through five years, and at ASCO this year we presented some of the update data,
?our recent ESMO event um we presented some of that. We learned a tremendous amount from the 34 neo antigens that we put into those people in that study. Um What is remarkable is you know, with the melanoma study that's just read out, we've taken the number of patients up that we have that experience with by almost a factor of 10.

And if you look across the other nine studies that are up and running, we'll go another factor of five again. And so we're starting to develop a tremendous amount of real experience with what sorts of neoantigens are generating T cell clones. What are the features of
that T cell clonality that we think is really valuable for a neoantigen vaccine, an individualized neoantigen vaccine.

And we are constantly looking to bring that back into how we predict and design INTs for individuals going forward. That data, that data is a gold
mine.

Passages & reports (13)
  • Great. Thank you for that question. So, first of all, yes, obviously the uh algorithm for …
  • it.
  • Um and that is a proprietary uh feature of our platform, our technology. It's not somethin…
  • what we've learned in our clinical trials. And bear in
  • mind,
  • you know, the randomized data we have on immunogenicity from the phase two was in
  • you
  • know about 150 people, about 100 people who received INT. There's now been followed throug…
  • our
  • recent ESMO event um we presented some of that. We learned a tremendous amount from the 34…
  • with by almost a factor of 10. And if you look across the other nine studies that are up a…
  • that T cell clonality that we think is really valuable for a neoantigen vaccine, an indivi…
  • mine.

Speaker 4

It's gone up by a factor of 10. And we will be with our partner deeply going through that data and continuing to treat that proprietary information as one of the really special sauces as we continue to try and make INTs more and more effective going forward in the you know, really in the decades ahead. So we think we're at the very beginning of a scientific revolution, and we're excited to be in the lead and to have that proprietary information.

Passages & reports (2)
  • It's gone up by a factor of 10. And we will be with our partner deeply going through that …
  • decades ahead. So we think we're at the very beginning of a scientific revolution, and we'…

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

One moment for our next question.

Passages & reports (1)
  • One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Michael Yi with UBS. Your line is

Passages & reports (1)
  • next question comes from Michael Yi with UBS. Your line is

Speaker unclear

?open. Hey guys, thanks. Good morning.

Passages & reports (1)
  • open. Hey guys, thanks. Good morning.

Speaker 6

Two questions. On uh on INT, uh the clinical trial protocols ?uh are available ?for renal cell and bladder cancer,

Passages & reports (5)
  • Two questions. On uh on INT, uh the clinical trial protocols
  • uh are
  • available
  • for
  • renal cell and bladder cancer,

Speaker unclear

?and we

Passages & reports (1)
  • and we

Speaker 2

understand that they are a uh alpha spend, uh one sided

Passages & reports (1)
  • understand that they are a uh alpha spend, uh one sided

Speaker unclear

?alpha

Passages & reports (1)
  • alpha

Speaker 6

of 0.10, very much like you nicely designed your phase ?two melanoma study,

Passages & reports (3)
  • of 0.10, very much like you nicely designed your phase
  • two
  • melanoma study,

Speaker unclear

?and very much the same

Passages & reports (1)
  • and very much the same

Speaker 6

assumptions. Do you um uh stand by that uh uh protocol and uh can confirm that those assumptions are are correct? And the second question is as it relates to filing in melanoma, um is there a general uh timing guidance for that? Um just so we can think about uh the gating steps and all the things that need to be done there in terms of the filing.

Thank

Passages & reports (2)
  • assumptions. Do you um uh stand by that uh uh protocol and uh can confirm that those assum…
  • think about uh the gating steps and all the things that need to be done there in terms of …

Speaker unclear

?you. Hi,

Passages & reports (1)
  • you. Hi,

Speaker 2

Michael.

Passages & reports (1)
  • Michael.

Speaker 3

Um we're not aware of um the protocols

Passages & reports (1)
  • Um we're not aware of um the protocols

Speaker 2

that you cite and uh you know obviously can't comment on it so I'm gonna have to pass on that in terms of the BLA we're obviously working closely with Merck on that and uh stay tuned for our next um message on

Passages & reports (1)
  • that you cite and uh you know obviously can't comment on it so I'm gonna have to pass on t…

Speaker unclear

?that

Passages & reports (1)
  • that

Speaker 0

thank you one moment for our next question

Passages & reports (1)
  • thank you one moment for our next question

Speaker unclear

?our

Passages & reports (1)
  • our

Speaker 0

next question comes from Courtney Breden with Bernstein your line is

Passages & reports (1)
  • next question comes from Courtney Breden with Bernstein your line is

Speaker unclear

?open hi

Passages & reports (1)
  • open hi

Speaker 5

Madonna team thanks so much for taking the question um a a couple for me I did want to zoom back to the pancreatic cancer study, the phase one data that you presented at ESMO this year. Obviously we saw the the the neoantigen uh generation, the T cell expansion, etc., that you've spoken to. There was also a small swimmer plot of uh of kind of performance for these patients and recurrence details for these patients.

Can you just help
?us uh understand what you're taking from that efficacy data so far? We see it as as relatively early compared to kind of what performance can be generated with full-fairy notes on its own. But just want to understand kind of what you're already able to take from those insights in the potential to move forward, or do you need more time to assess that data before you would move forward?

And then just
?the second question, just a really practical one on the on that revenue generation. ?Can you just talk a little bit about the XUS components here and how much of that is coming from kind of commitments, uh, how much of that is coming from pure demand, and uh we're just trying to figure out how we how we kind of appropriately carry uh some of this forward.

Thank you
so

Passages & reports (10)
  • Madonna team thanks so much for taking the question um a a couple for me I did want to zoo…
  • There was also a small swimmer plot of uh of kind of performance for these patients and re…
  • us
  • uh understand what you're taking from that efficacy data so far? We see it as as relativel…
  • to move forward, or do you need more time to assess that data before you would move forwar…
  • the
  • second question, just a really practical one on the on that revenue generation.
  • Can
  • you just talk a little bit about the XUS components here and how much of that is coming fr…
  • so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Courtney, thank you very much for this, David. Thank you for the pancreatic uh question. Um it was very

Passages & reports (1)
  • Courtney, thank you very much for this, David. Thank you for the pancreatic uh question. U…

Speaker 3

exciting data because we can generate um T cells reactive to neoantigens that are present in uh the PDAC

Passages & reports (1)
  • exciting data because we can generate um T cells reactive to neoantigens that are present …

Speaker 2

patients,

Passages & reports (1)
  • patients,

Speaker 3

which is

Passages & reports (1)
  • which is

Speaker 2

something that actually

Passages & reports (1)
  • something that actually

Speaker 3

was not really

Passages & reports (1)
  • was not really

Speaker 2

uh necessarily given. ?In terms of the swimmer plot um that you notice, yes,

Passages & reports (3)
  • uh necessarily given.
  • In
  • terms of the swimmer plot um that you notice, yes,

Speaker 3

um I think I agree that it's probably too early, point number one. And point number two, this was a mix of patients. Some of them had neoadriven treatment, some of them didn't, and so it's really hard for us to discern an efficacy signal. I'm I'm I'm always careful about discerning efficacy signals in single arm trial to event uh time to event analyses.

Um I think the immunogenicities data are great, the safeties are great, and we'll have to figure out the next uh
Question

Passages & reports (3)
  • um I think I agree that it's probably too early, point number one. And point number two, t…
  • single arm trial to event uh time to event analyses. Um I think the immunogenicities data …
  • Question

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 2

international. So I would

Passages & reports (1)
  • international. So I would

Speaker unclear

?say

Passages & reports (1)
  • say

Speaker 3

a significant portion is very durable. We've talked about these strategic partnerships, and it comprises over 50% of our revenue for sure. And then, but I think what's also great about our international growth is one, we're playing in a lot of other markets outside of these strategic partnerships that we have been for some time. And we are increasing share to some degree. As well as I think as I mentioned earlier, the vaccination rates are improving in a lot of these markets markets as well.

So I think we are seeing a shift year over year globally that vaccination rates have become more stable.
?So we hope that that is pretty durable moving forward.

Passages & reports (4)
  • a significant portion is very durable. We've talked about these strategic partnerships, an…
  • time. And we are increasing share to some degree. As well as I think as I mentioned earlie…
  • So
  • we hope that that is pretty durable moving forward.

Speaker 5

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

One moment for our next question.

Passages & reports (1)
  • One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Alexandria Hadman of Wolf Research. Your line is

Passages & reports (1)
  • next question comes from Alexandria Hadman of Wolf Research. Your line is

Speaker unclear

?open. Hey

Passages & reports (1)
  • open. Hey

Speaker 5

guys, thanks for taking the question.

Passages & reports (1)
  • guys, thanks for taking the question.

Speaker 7

So ?on INT, what learnings ?have you guys been able to take in regard to the

Passages & reports (5)
  • So
  • on
  • INT, what learnings
  • have
  • you guys been able to take in regard to the

Speaker 5

optimal number ?of neoantigens coded? Do you think 34 is a sweet spot, or do you think essentially next generation assets or of your internal kind of uh platform could encompass more? ?I guess what kind of has the data demonstrated about how much of the breadth of these new antigen payload matters? Is more always better, or could a smaller number of really highly immunogenic new antigens be more favorable?

Thank

Passages & reports (5)
  • optimal number
  • of
  • neoantigens coded? Do you think 34 is a sweet spot, or do you think essentially next gener…
  • I
  • guess what kind of has the data demonstrated about how much of the breadth of these new an…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

I love the science question ?and I'm I'm happy to take it

Passages & reports (3)
  • I love the science question
  • and I'm
  • I'm happy to take it

Speaker 3

and expound on it. Um You're asking the

Passages & reports (1)
  • and expound on it. Um You're asking the

Speaker 2

exact question, right? Which is what makes an optimal neoantigen, how many you need. These are things that we are now looking into because we have a randomized phase three

Passages & reports (1)
  • exact question, right? Which is what makes an optimal neoantigen, how many you need. These…

Speaker 3

trial.

Passages & reports (1)
  • trial.

Speaker unclear

?And you need

Passages & reports (1)
  • And you need

Speaker 2

the efficacy in order to decode, go back to how many neoantigens you you actually need. So in melanoma, which has several hundred neoantigens to choose from, we know that 34 selected is enough. We can see that uh m roughly one out of three of them generate a T cell response, although that may be higher. It actually we're learning that we may actually have more immunogenicity than we actually thought we ?did.

So um I'm not sure more is better because
?a ha I'm not sure you know a hazard ratio of zero point five eight

Passages & reports (6)
  • the efficacy in order to decode, go back to how many neoantigens you you actually need. So…
  • although that may be higher. It actually we're learning that we may actually have more imm…
  • did.
  • So um I'm not sure more is better because
  • a
  • ha I'm not sure you know a hazard ratio of zero point five eight

Speaker 3

or zero point five one in the MITT is pretty good. I against K Truda, it's really, really good. So would more have been better? Uh it's hard to imagine more would have been better, but I don't know. These are things we now need to decode ?with our phase three data.

Passages & reports (3)
  • or zero point five one in the MITT is pretty good. I against K Truda, it's really, really …
  • with
  • our phase three data.

Speaker 0

Thank you. One moment for our next question.

Passages & reports (1)
  • Thank you. One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Jess Five with JP Morgan. Your line is

Passages & reports (1)
  • next question comes from Jess Five with JP Morgan. Your line is

Speaker unclear

?open.

Passages & reports (1)
  • open.

Speaker unclear

?Hey guys, um thanks

Passages & reports (1)
  • Hey guys, um thanks

Speaker 5

for taking my question. Just following up on Alex's question there, you mentioned now you have the sort of treasure trove of phase three data. If I recall from the phase two with the translational work we saw at Ask, there were ?like seven patients to work with and it was like a maybe a little hard to draw conclusions based on the small sample size.

Do you have the actual like samples and you know data that you need to run that analysis to figure out those answers about sort of optimal number of muantigens?

Passages & reports (3)
  • for taking my question. Just following up on Alex's question there, you mentioned now you …
  • like
  • seven patients to work with and it was like a maybe a little hard to draw conclusions base…

Speaker unclear

?Jess,

Passages & reports (1)
  • Jess,

Speaker 2

thanks. Um ?so the seven patients that you talk about is correct, the N equals seven, because in order to do very deep immunological monitoring, you have ?to withdraw um a decent amount of blood. And not all patients are willing to do that. And in this case there were seven patients willing to do ?that. We do have more patients available from across the trial.

So that's point number one.

Passages & reports (7)
  • thanks. Um
  • so
  • the seven patients that you talk about is correct, the N equals seven, because in order to…
  • to
  • withdraw um a decent amount of blood. And not all patients are willing to do that. And in …
  • that.
  • We do have more patients available from across the trial. So that's point number one.

Speaker 3

And secondly we have developed really exciting novel ways to

Passages & reports (1)
  • And secondly we have developed really exciting novel ways to

Speaker 2

decode T cell reactivity from gene from just looking at the expression data from the from the from the uh whole blood gene analysis ?uh TCR beta we we have a way that we're beginning to learn to try ?to decode back neoantigen specificity. I mean, that's part of the holy grail. So I am hopeful that we will be able to get insights from the phase three that we didn't have in the phase two.

I think that um it remains to be seen how far we can go, but that is the uh
that is certainly the goal.

Passages & reports (6)
  • decode T cell reactivity from gene from just looking at the expression data from the from …
  • uh
  • TCR beta we we have a way that we're beginning to learn to try
  • to
  • decode back neoantigen specificity. I mean, that's part of the holy grail. So I am hopeful…
  • that is certainly the goal.

Speaker unclear

?Thanks.

Passages & reports (1)
  • Thanks.

Speaker 0

One moment for our next question.

Passages & reports (1)
  • One moment for our next question.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Luca IC with RBC. Your line's open.

Passages & reports (1)
  • next question comes from Luca IC with RBC. Your line's open.

Speaker unclear

?Oh, great.

Passages & reports (1)
  • Oh, great.

Speaker 2

Thanks so much for doing my ?question. Congrats on all the progress. Maybe David, one more on RCC and the upcoming phase two. Can you just maybe

Passages & reports (3)
  • Thanks so much for doing my
  • question.
  • Congrats on all the progress. Maybe David, one more on RCC and the upcoming phase two. Can…

Speaker 6

talk about the stratification

Passages & reports (1)
  • talk about the stratification

Speaker unclear

?strategy there? It looks like

Passages & reports (1)
  • strategy there? It looks like

Speaker 2

you're stratifying patients by either clear cell ?versus populary histology, as well ?as by high ?versus low disease risk.

Passages & reports (7)
  • you're stratifying patients by either clear cell
  • versus populary
  • histology, as well
  • as
  • by high
  • versus low
  • disease risk.

Speaker unclear

?I guess what I'm trying to ask is there any specific subpopulations within RCC that you are that are maybe more immunologically

Passages & reports (1)
  • I guess what I'm trying to ask is there any specific subpopulations within RCC that you ar…

Speaker 6

active that you're ?more optimistic that this

Passages & reports (3)
  • active that you're
  • more
  • optimistic that this

Speaker unclear

?approach can work or do you think that this can work kind of across the board? And then maybe related to it, are you tracking the blinded event rate for progressions and debt and are they on track with internal expectations

Passages & reports (1)
  • approach can work or do you think that this can work kind of across the board? And then ma…

Speaker 6

or not? ?And then maybe separately, Steve, any update on the ongoing conversations

Passages & reports (3)
  • or not?
  • And
  • then maybe separately, Steve, any update on the ongoing conversations

Speaker unclear

?with the

Passages & reports (1)
  • with the

Speaker 2

FDA on the timelines for COVID plus flu in the US? Thanks so

Passages & reports (1)
  • FDA on the timelines for COVID plus flu in the US? Thanks so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 3

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

um in terms of

Passages & reports (1)
  • um in terms of

Speaker 3

the tracking of the events, we don't comment on that. Uh in terms of the ?uh what

Passages & reports (3)
  • the tracking of the events, we don't comment on that. Uh in terms of the
  • uh
  • what

Speaker 2

subpopulations, um I think we believe this can work in multiple subpopulations. I think that was one of the insights we made from the phase two and the phase three study ?that pretty much all of the subsets we looked at have had a trend or a point estimate in favor of intismerate, including uh high stage versus low stage, high TMB versus low TMB.

Um some subtypes, papillary renal cell, obviously is different than clear cell RCC, but that's why we're um stratifying against
?that. But uh as long as they have new antigens, we think that we can generate novel T cell phones and that can potentially have benefits. So ?I don't think I would narrow down to a population right

Passages & reports (7)
  • subpopulations, um I think we believe this can work in multiple subpopulations. I think th…
  • that
  • pretty much all of the subsets we looked at have had a trend or a point estimate in favor …
  • that.
  • But uh as long as they have new antigens, we think that we can generate novel T cell phone…
  • I
  • don't think I would narrow down to a population right

Speaker unclear

?now.

Passages & reports (1)
  • now.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Later

Passages & reports (1)
  • you. Later

Speaker 4

and then I'll

Passages & reports (1)
  • and then I'll

Speaker 0

sorry

Passages & reports (1)
  • sorry

Speaker 4

um just on the question on uh the the flu uh COVID combo vaccine for the US um we um uh you know as we as we said before we were waiting for the approval in August um that was just two months ago um and then the launch um of the flu and COVID vaccines in the US. Um and that was our key to then start the process of engaging with the FDA deck will take some time.

Um there's a lot going on right now um across our whole portfolio. And so we will in the next number of months uh be able to sit down uh
and understand better uh what the uh US FDA expects in terms of submission of uh the 10 A three program. Um and once we have that information we'll um obviously provide an update.

Passages & reports (3)
  • um just on the question on uh the the flu uh COVID combo vaccine for the US um we um uh yo…
  • vaccines in the US. Um and that was our key to then start the process of engaging with the…
  • and understand better uh what the uh US FDA expects in terms of submission of uh the 10 A …

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 6

right, thanks so much, guys.

Passages & reports (1)
  • right, thanks so much, guys.

Speaker unclear

?Well,

Passages & reports (1)
  • Well,

Speaker 0

ladies and gentlemen, that's concluded the QA portion of today's program. I'd like to turn the club back over to Stefan for any further remarks.

Passages & reports (1)
  • ladies and gentlemen, that's concluded the QA portion of today's program. I'd like to turn…

Speaker 3

Well, thank you everybody for joining us today. We really appreciate it.

Passages & reports (1)
  • Well, thank you everybody for joining us today. We really appreciate it.

Speaker unclear

?We're looking

Passages & reports (1)
  • We're looking

Speaker 2

forward to seeing many of you in person next week for annual analysis november twelfth. And we're very excited for you to tour and to discover the Intismeran manufacturing site. Have a nice weekend.

Passages & reports (1)
  • forward to seeing many of you in person next week for annual analysis november twelfth. An…

Speaker 0

Thank you, ladies and gentlemen. So that's concluded today's presentation. We thank you for your participation. You may now disconnect and have a wonderful day.

Passages & reports (1)
  • Thank you, ladies and gentlemen. So that's concluded today's presentation. We thank you fo…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 598. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T00:56:58.061Z.
Transcript version v1-c53f89cec0c17ac2fb12 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.